Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Gram-Negative Infections | Current Treatment: Physician Insights | US | 2018

Login to access report north_east
Contact sales account_box

MARKET OUTLOOK

Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with these agents, making it difficult for branded products like Merck & Co.’s Zerbaxa, Allergan’s Avycaz, and Melinta’s Vabomere to gain uptake in earlier lines of therapy. However, rising antimicrobial resistance rates have created the need for safer products to effectively treat drug-resistant GNIs, and, as our primary market research shows, activity against key drug-resistant pathogens is an important driver of brand use. Furthermore, hospital-based infectious disease (ID) specialists report shifts in their approach to treating GNIs in response to the climbing rates of drug resistance.

QUESTIONS ANSWERED

  • What are the most prescribed first-, second-, and third-line therapies for inpatients with a urinary tract infection, nosocomial pneumonia, or complicated intra-abdominal infection?
  • How are physicians approaching the treatment of infections caused by drug-resistant pathogens?
  • Which clinical and nonclinical factors drive, and prevent, the prescribing of brand agents such as Zerbaxa, Avycaz, and Tygacil? What are the most common therapies that patients receive prior to being prescribed Zerbaxa,  Avycaz or Tygacil?
  • What will be the impact of the recent approval of Vabomere? What will drive its use and in which populations will it be used? Which current agents will be most affected by its prescribing?

PRODUCT DESCRIPTION

Provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that you can create specific messaging around these treatment dynamics to more effectively increase or defend your market position.

Markets covered: United States

Primary research: Survey of 104 hospital-based ID specialists in the United States

Key drugs: Avycaz, Zerbaxa, Vabomere, Invanz, Teflaro, Tygacil, Minocin, and other key GNI generic drugs

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Multiple Myeloma – Current Treatment – Current Treatment: Physician Insights – Multiple Myeloma (US)
Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…
north_east
Report
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east